{"id":1644,"date":"2021-10-15T12:50:00","date_gmt":"2021-10-15T12:50:00","guid":{"rendered":"https:\/\/www.prnasia.com\/story\/archive\/3539683_CN39683_0"},"modified":"2021-10-15T12:50:00","modified_gmt":"2021-10-15T12:50:00","slug":"cellorigin-secured-a-new-round-of-investment-for-developing-its-globally-proprietary-ipsc-car-macrophage-technology-platform","status":"publish","type":"post","link":"https:\/\/transmediavictoria.net.au\/?p=1644","title":{"rendered":"CellOrigin secured a new round of investment for developing its globally proprietary iPSC-CAR-Macrophage technology platform"},"content":{"rendered":"<p><span class=\"xn-location\">HANGZHOU, China<\/span>, <span class=\"xn-chron\">Oct. 15, 2021<\/span> \/PRNewswire\/ &#8212; On <span class=\"xn-chron\">Oct. 11<\/span><sup>th<\/sup>, 2021, CellOrigin Inc. released data about its second generation of iPSC-CAR-Macrophage which has a genetically integrated secondary signal to confer controlled CAR-iMac polarization, in the 5<sup>th<\/sup> International Conference of IGC China, 2021, <span class=\"xn-location\">Beijing<\/span>. <\/p>\n<p>Recently, CellOrigin Biotech, a company committed to iPSC-derived innate immune cell therapeutics, has announced a new round of investment by Kunlun Capital. The investment will be used for the CMC development for its current pipeline of iPSC-derived innate immune cells such as iPSC-CAR-Macrophage and rationlly designed iPSC-NK cells. Before, CellOrigin have also acquired investment from Shulan Health and Nest. Bio Ventures. <\/p>\n<p>CellOrigin Biotech has a long term focus on iPSC-derived innate immune cells and its applications in new cancer immune cells. Dr. <span class=\"xn-person\">Jin Zhang<\/span>, the scientific co-founder of CellOrigin used to be trained as a research fellow at the Boston Children&#8217;s Hospital and <span class=\"xn-org\">Harvard Medical School<\/span>. Now, his team worked closely with clinicians at the First Affiliated Hospital of <span class=\"xn-location\">Zhejiang<\/span> University, and for the first time his team reported the induced pluripotent stem cell or iPSC-derived CAR-macrophages (CAR-iMac), and its applications in cancer immunotherapies. <\/p>\n<p>CellOrigin Biotech holds the domestic and global patents for iPSC-derived CAR-Macrophage, and the engineering for polarization. With this proprietary platform, they are collaborating with research groups in genome engineering and synthetic biology worldwide to fully unleash the potential of iPSC-derived immune cells, which are highly editable, expandable and clonal. Eventually, they would like to achieve a goal of bring more effective, universal and safe immune cell products to cancer patients, especially for those with solid tumors. The investigator initiated trials has been initiated at the First Hospital of <span class=\"xn-location\">Zhejiang<\/span> University. The core proprietary technology platform and the core patents including the engineered macrophages from pluripotent stem cells has been authorized and is in the process of entering different countries worldwide.<\/p>\n<p>To support the CMC of its pipeline products, on <span class=\"xn-chron\">Oct 1<\/span><sup>st<\/sup>, CellOrigin&nbsp;has announced the launch of its 3000 square feet GMP facility at <span class=\"xn-location\">Hangzhou, China<\/span>. <\/p>\n<p>About Kunlun Capital<\/p>\n<p>Founded in 2015, Kunlun capital is committed to long-term value investment, establishing long-term partnership with entrepreneurs, and focusing on investing in enterprises with high technical barriers, excellent founding team and explosive growth potential. In recent years, Kunlun capital has successively invested in KEYA Medical, EdiGene, Cytek (NASDAQ:CTKB), Hui-Gene Therapeutics, OBiO, Okeanos, Ucell Biotech, CellOrigin, Soonsolid, Inke (HK:03700), Dada (NASDAQ:DADA), Dreame, Bamboocloud, Pony.ai, PingCAP, Leyan Technologies.<\/p>\n<p id=\"PURL\"><img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/c212.net\/c\/img\/favicon.png?sn=CN39683&amp;sd=2021-10-15\"> View original content:<a id=\"PRNURL\" rel=\"nofollow noopener\" href=\"https:\/\/www.prnewswire.com\/news-releases\/cellorigin-secured-a-new-round-of-investment-for-developing-its-globally-proprietary-ipsc-car-macrophage-technology-platform-301401007.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/cellorigin-secured-a-new-round-of-investment-for-developing-its-globally-proprietary-ipsc-car-macrophage-technology-platform-301401007.html<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>HANGZHOU, China, Oct. 15, 2021 \/PRNewswire\/ &#8212; On Oct. 11th, 2021, CellOrigin Inc. released data about its second generation of iPSC-CAR-Macrophage which has a genetically integrated secondary signal to confer controlled CAR-iMac polarization, in the 5th International Conference of IGC China, 2021, Beijing. Recently, CellOrigin Biotech, a company committed to iPSC-derived innate immune cell therapeutics, [&hellip;]<\/p>\n","protected":false},"author":8,"featured_media":1645,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-1644","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-business-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CellOrigin secured a new round of investment for developing its globally proprietary iPSC-CAR-Macrophage technology platform - My Blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/transmediavictoria.net.au\/?p=1644\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CellOrigin secured a new round of investment for developing its globally proprietary iPSC-CAR-Macrophage technology platform - My Blog\" \/>\n<meta property=\"og:description\" content=\"HANGZHOU, China, Oct. 15, 2021 \/PRNewswire\/ &#8212; On Oct. 11th, 2021, CellOrigin Inc. released data about its second generation of iPSC-CAR-Macrophage which has a genetically integrated secondary signal to confer controlled CAR-iMac polarization, in the 5th International Conference of IGC China, 2021, Beijing. Recently, CellOrigin Biotech, a company committed to iPSC-derived innate immune cell therapeutics, [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/transmediavictoria.net.au\/?p=1644\" \/>\n<meta property=\"og:site_name\" content=\"My Blog\" \/>\n<meta property=\"article:published_time\" content=\"2021-10-15T12:50:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2021\/10\/cellorigin-secured-a-new-round-of-investment-for-developing-its-globally-proprietary-ipsc-car-macrophage-technology-platform.png\" \/>\n\t<meta property=\"og:image:width\" content=\"16\" \/>\n\t<meta property=\"og:image:height\" content=\"16\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin_tony\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin_tony\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=1644#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=1644\"},\"author\":{\"name\":\"admin_tony\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"headline\":\"CellOrigin secured a new round of investment for developing its globally proprietary iPSC-CAR-Macrophage technology platform\",\"datePublished\":\"2021-10-15T12:50:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=1644\"},\"wordCount\":424,\"image\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=1644#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/transmediavictoria.net.au\\\/wp-content\\\/uploads\\\/2021\\\/10\\\/cellorigin-secured-a-new-round-of-investment-for-developing-its-globally-proprietary-ipsc-car-macrophage-technology-platform.png\",\"articleSection\":[\"Business News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=1644\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=1644\",\"name\":\"CellOrigin secured a new round of investment for developing its globally proprietary iPSC-CAR-Macrophage technology platform - My Blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=1644#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=1644#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/transmediavictoria.net.au\\\/wp-content\\\/uploads\\\/2021\\\/10\\\/cellorigin-secured-a-new-round-of-investment-for-developing-its-globally-proprietary-ipsc-car-macrophage-technology-platform.png\",\"datePublished\":\"2021-10-15T12:50:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=1644#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=1644\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=1644#primaryimage\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/wp-content\\\/uploads\\\/2021\\\/10\\\/cellorigin-secured-a-new-round-of-investment-for-developing-its-globally-proprietary-ipsc-car-macrophage-technology-platform.png\",\"contentUrl\":\"https:\\\/\\\/transmediavictoria.net.au\\\/wp-content\\\/uploads\\\/2021\\\/10\\\/cellorigin-secured-a-new-round-of-investment-for-developing-its-globally-proprietary-ipsc-car-macrophage-technology-platform.png\",\"width\":16,\"height\":16},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?p=1644#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CellOrigin secured a new round of investment for developing its globally proprietary iPSC-CAR-Macrophage technology platform\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#website\",\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/\",\"name\":\"My Blog\",\"description\":\"My WordPress Blog\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/transmediavictoria.net.au\\\/#\\\/schema\\\/person\\\/5b51d407d652c0aa802bea269ea5d7e7\",\"name\":\"admin_tony\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g\",\"caption\":\"admin_tony\"},\"url\":\"https:\\\/\\\/transmediavictoria.net.au\\\/?author=8\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CellOrigin secured a new round of investment for developing its globally proprietary iPSC-CAR-Macrophage technology platform - My Blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/transmediavictoria.net.au\/?p=1644","og_locale":"en_US","og_type":"article","og_title":"CellOrigin secured a new round of investment for developing its globally proprietary iPSC-CAR-Macrophage technology platform - My Blog","og_description":"HANGZHOU, China, Oct. 15, 2021 \/PRNewswire\/ &#8212; On Oct. 11th, 2021, CellOrigin Inc. released data about its second generation of iPSC-CAR-Macrophage which has a genetically integrated secondary signal to confer controlled CAR-iMac polarization, in the 5th International Conference of IGC China, 2021, Beijing. Recently, CellOrigin Biotech, a company committed to iPSC-derived innate immune cell therapeutics, [&hellip;]","og_url":"https:\/\/transmediavictoria.net.au\/?p=1644","og_site_name":"My Blog","article_published_time":"2021-10-15T12:50:00+00:00","og_image":[{"width":16,"height":16,"url":"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2021\/10\/cellorigin-secured-a-new-round-of-investment-for-developing-its-globally-proprietary-ipsc-car-macrophage-technology-platform.png","type":"image\/png"}],"author":"admin_tony","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin_tony","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/transmediavictoria.net.au\/?p=1644#article","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/?p=1644"},"author":{"name":"admin_tony","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"headline":"CellOrigin secured a new round of investment for developing its globally proprietary iPSC-CAR-Macrophage technology platform","datePublished":"2021-10-15T12:50:00+00:00","mainEntityOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=1644"},"wordCount":424,"image":{"@id":"https:\/\/transmediavictoria.net.au\/?p=1644#primaryimage"},"thumbnailUrl":"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2021\/10\/cellorigin-secured-a-new-round-of-investment-for-developing-its-globally-proprietary-ipsc-car-macrophage-technology-platform.png","articleSection":["Business News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/transmediavictoria.net.au\/?p=1644","url":"https:\/\/transmediavictoria.net.au\/?p=1644","name":"CellOrigin secured a new round of investment for developing its globally proprietary iPSC-CAR-Macrophage technology platform - My Blog","isPartOf":{"@id":"https:\/\/transmediavictoria.net.au\/#website"},"primaryImageOfPage":{"@id":"https:\/\/transmediavictoria.net.au\/?p=1644#primaryimage"},"image":{"@id":"https:\/\/transmediavictoria.net.au\/?p=1644#primaryimage"},"thumbnailUrl":"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2021\/10\/cellorigin-secured-a-new-round-of-investment-for-developing-its-globally-proprietary-ipsc-car-macrophage-technology-platform.png","datePublished":"2021-10-15T12:50:00+00:00","author":{"@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7"},"breadcrumb":{"@id":"https:\/\/transmediavictoria.net.au\/?p=1644#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/transmediavictoria.net.au\/?p=1644"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/transmediavictoria.net.au\/?p=1644#primaryimage","url":"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2021\/10\/cellorigin-secured-a-new-round-of-investment-for-developing-its-globally-proprietary-ipsc-car-macrophage-technology-platform.png","contentUrl":"https:\/\/transmediavictoria.net.au\/wp-content\/uploads\/2021\/10\/cellorigin-secured-a-new-round-of-investment-for-developing-its-globally-proprietary-ipsc-car-macrophage-technology-platform.png","width":16,"height":16},{"@type":"BreadcrumbList","@id":"https:\/\/transmediavictoria.net.au\/?p=1644#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/transmediavictoria.net.au\/"},{"@type":"ListItem","position":2,"name":"CellOrigin secured a new round of investment for developing its globally proprietary iPSC-CAR-Macrophage technology platform"}]},{"@type":"WebSite","@id":"https:\/\/transmediavictoria.net.au\/#website","url":"https:\/\/transmediavictoria.net.au\/","name":"My Blog","description":"My WordPress Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/transmediavictoria.net.au\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/transmediavictoria.net.au\/#\/schema\/person\/5b51d407d652c0aa802bea269ea5d7e7","name":"admin_tony","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/102836fe5f9cd6c64e96e90e7341dbc815b7d12726a85708326dc0db40afd906?s=96&d=mm&r=g","caption":"admin_tony"},"url":"https:\/\/transmediavictoria.net.au\/?author=8"}]}},"_links":{"self":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/1644","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1644"}],"version-history":[{"count":0,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/posts\/1644\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=\/wp\/v2\/media\/1645"}],"wp:attachment":[{"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1644"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1644"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/transmediavictoria.net.au\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1644"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}